Meryem İlkay EREN KARANİS, Yaşar ÜNLÜ, Mustafa EROL

The importance of SUV max in predicting prognosis of invasive breast carcinoma-no special types

Aim: We aimed to investigate the relationship between FDG uptake and clinicopathological characteristics of invasive breast carcinoma-no special type in the present study.Materials and Methods: One hundred seventy invasive breast carcinoma-no special type cases who underwent PET-CT before surgery between 2011-2019 were included in the study. The clinicopathological features and SUVmax of the patients were compared.Results: We observed a strong relationship between the size, grade, pathological stage groups and SUVmax of the tumors and revealed that the SUVmax increased as the size, grade, and pathological stage groups of the tumors increased (p

PDF

___

1. Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics. CA Cancer J Clin 2017;67:177-93.
2. Harbeck N, Thomssen C, Gnant M. St. Gallen 2013: brief preliminary summary of the consensus discussion. Breast care 2013;8:102-9.
3. Savage P, Yu N, Dumitra S, et al. The effect of the American Joint Committee on Cancer eighth edition on breast cancer staging and prognostication. Eur J Surg Oncol 2019;45:1817-20.
4. Nakajo M, Kajiya Y, Kaneko T, et al. FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion. Eur J Nucl Med Mol Imaging 2010;37:2011-20.
5. Abubakar ZA, Akepati NKR, Bikkina P. Correlation of maximum standardized uptake values in 18F-Fluorodeoxyglucose positron emission tomography-computed tomography scan with immunohistochemistry and other prognostic factors in breast cancer. Indian J Nucl Med 2019;34:10.
6. Prognostic and predictive factors in early, nonmetastatic breast cancer. https://www.uptodate. com/contents/prognostic-and-predictive-factors-inmetastatic- breast-cancer access date 13.02.2019.
7. Nishimura R, Osako T, Okumura Y, et al. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med 2010;1:747-54.
8. Weiss A, Chavez-MacGregor M, Lichtensztajn DY, et al. Validation study of the American Joint Committee on Cancer eighth edition prognostic stage compared with the anatomic stage in breast cancer. JAMA oncology 2018;4:203-9.
9. Fallahpour S, Navaneelan T, De P, et al. Breast cancer survival by molecular subtype: a populationbased analysis of cancer registry data. CMAJ open 2017;5:E734.
10. Sanli Y, Kuyumcu S, Ozkan ZG, et al. Increased FDG uptake in breast cancer is associated with prognostic factors. Ann Nucl Med 2012;26:345-50.
11. Choi BB, Kim SH, Kang BJ, et al. Diffusion-weighted imaging and FDG PET/CT: predicting the prognoses with apparent diffusion coefficient values and maximum standardized uptake values in patients with invasive ductal carcinoma. World J Surg Oncol 2012;10:126.
12. Groheux D, Giacchetti S, Moretti JL, et al. Correlation of high 18 F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 2011;38:426-35.
13. Groheux D, Giacchetti S, Moretti JL, et al. Correlation of high 18 F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 2011;38(3):426-435.
14. Kim BS, Sung SH. Usefulness of 18 F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. Ann Nucl Med 2012;26:175-83.